US Stock MarketDetailed Quotes

ONVO Organovo Holdings

Watchlist

0.537
-0.011-1.92%

Trading Aug 8 15:44 ET

8.25MMarket Cap-392P/E (TTM)

Organovo Holdings Stock Forum

Jaguar8

Jul 16 08:41

NEWS

$Organovo Holdings (ONVO.US)$
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis...

Jaguar8

May 8 19:01

$Organovo Holdings (ONVO.US)$
NEWS
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Stock Region

Apr 16 07:16

3D Printing Biotech Company Announces Positive Results For Fatty Liver Disease Treatment

Breakthrough in MASH Treatment: Organovo's FXR314 Shows Promising Phase 2 Results
In a significant step forward for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Organovo Holdings Inc. has announced positive Phase 2 trial results for its experimental drug, FXR314. This development marks a pivotal moment in the fight against MASH, a severe form of fatty liver disease that poses a su...